Groundbreaking Advances in Cancer Immunotherapy
In a noteworthy development, Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a pioneering clinical-stage biopharmaceutical company, has shared exciting data regarding its CAPTN-3 tri-specific antibody, IM1240. This innovative therapy is being designed in collaboration with the renowned Icahn School of Medicine at Mount Sinai, under the leadership of the esteemed researcher Dr. Amir Horowitz.
Collaboration Highlights
The collaboration has yielded significant insights, particularly in dissecting how IM1240 interacts with treatment-resistant cancers. Dr. Horowitz has been evaluating the impact of this tri-specific antibody on patient-derived tumor biopsies. These unique biopsies maintain the complexity of tumor cell heterogeneity and immune cell interactions in the microenvironment, closely mirroring the clinical conditions faced by cancer patients.
Evaluation of Treatment-Resistant Cancers
This research is particularly focused on prevalent and challenging cancers such as Non-Small Cell Lung Cancer (NSCLC), head and neck squamous cell carcinoma, and bladder cancer. These types illustrate a significant unmet medical need for innovative treatment strategies. According to Gil Efron, CEO of Purple Biotech, this collaboration is crucial for understanding the dynamics and efficacy of the CAPTN-3 platform in real-world scenarios.
Unique Properties of IM1240
A key feature of IM1240 is its ability to induce cancer cell apoptosis effectively, especially in head and neck cancers resistant to anti-PD1 therapy. In Dr. Horowitz’s findings, the tri-specific antibody engendered a significant response, unlike related bispecific variants that lack functional components. This underlines the distinct synergistic properties of the CD3 and NKG2A arms that are exclusive to Purple Biotech’s CAPTN-3 platform, enhancing its therapeutic potential against resistant cancer types.
Targeting Selective Checkpoints
One of the remarkable strategies of IM1240 is its focus on the NKG2A, a selective checkpoint inhibitor that inhibits tumor growth while aiming to minimize side effects. Diagrams emerging from clinical analysis suggest that NKG2A is predominantly expressed on cytotoxic lymphocytes, including Natural Killer (NK) cells and CD8+ T cells. This specificity makes the blockade of NKG2A a compelling option for enhancing anticancer responses.
Presented Findings at ASGCT Annual Meeting
Dr. Horowitz presented his significant findings on the NKG2A/HLA-E dynamic and its implications for cancer treatment at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). He elaborated on how the tri-specific antibodies designed by Purple Biotech can effectively activate immune cells that express NKG2A, a key player in the body’s immune response against tumors. Moreover, this approach emphasizes a safety profile with enhanced efficacy.
Research Endeavors of Dr. Horowitz
Dr. Horowitz serves as an Associate Professor of Immunology & Immunotherapy at the Icahn School of Medicine and is committed to advancing cancer treatment. His research aims to harness NK and CD8 T cells to effectively attack resistant tumors, with IM1240 being a crucial aspect of this work. The promising data surrounding the NKG2A/HLA-E interaction highlights its potential to redefine immunotherapeutic approaches using the CAPTN-3 platform.
About Purple Biotech
Purple Biotech (NASDAQ/TASE: PPBT) focuses on developing groundbreaking therapies that tackle cancer through immune evasion and drug resistance. The company is known for its rich pipeline that includes innovative therapies such as CM24 and NT219, alongside IM1240. This pipeline reflects Purple Biotech's commitment to leveraging cutting-edge immunotherapy to address the complexities of cancer treatment.
Among these developments is the company’s CAPTN-3 platform, which engages both T cells and NK cells, fostering localized immune responses within the tumor microenvironment. The design of these tri-specific antibodies strategically targets tumor-associated antigens to unleash both innate and adaptive immune systems. By confining therapeutic activities to tumor sites, Purple Biotech aims to enhance the safety and efficacy of its treatments.
The potential of CM24 and NT219 extends across various cancer indications, with CM24 now entering crucial phases of clinical trials. NT219, a dual inhibitor, has showcased promise in combination therapies targeting advanced head and neck cancer. Purple Biotech is heralding a new era in cancer treatment, with continual progress being observed in its clinical studies.
Frequently Asked Questions
What is IM1240?
IM1240 is a tri-specific antibody developed by Purple Biotech that targets 5T4, a tumor-associated antigen, and is part of the CAPTN-3 platform aimed at improving cancer treatments.
What are the main cancers being targeted with IM1240?
IM1240 is focused on cancers such as Non-Small Cell Lung Cancer, head and neck squamous cell carcinoma, and bladder cancer, particularly those resistant to existing therapies.
Who is leading the research for IM1240?
The research is led by Dr. Amir Horowitz at the Icahn School of Medicine at Mount Sinai, an expert in cancer immunology.
What makes IM1240 different from other cancer therapies?
IM1240 uniquely combines CD3 and NKG2A engagement, aiming to enhance therapeutic response while minimizing side effects through selective targeting of immune pathways.
When are clinical trials for IM1240 expected to start?
Clinical trials for IM1240 are scheduled to begin following an IND submission anticipated in the near future, positioning it for human trials.
